The newest drugs for hypertension mainly include the following: new dual-channel blocking calcium channel blockers, direct renin inhibitors, new aminopeptidase A inhibitors, sodium and potassium channel converting enzyme inhibitors and other drugs. 1. New dual-channel calcium channel blockers: the main representative drug is tylodipine hydrochloride, which can double block L-type and T-type calcium channels, and also has the effect of organ protection, and the incidence of peripheral edema in patients is lower, and better tolerability. 2. Direct renin inhibitors: Aliskiren is the only direct renin inhibitor currently on the market. Direct renin inhibitors can directly inhibit the production of renin, reduce the concentration of angiotensin II in the body, and antagonize the blood pressure-raising effect of angiotensin II. 3. New type of aminopeptidase A inhibitor: the main representative drug is felbamostat (currently not available in China), which specifically inhibits aminopeptidase A by delivering EC33 products in the brain, thus reducing the production of angiotensin II and lowering blood pressure. Research suggests that Felibastat can be used as a safe and effective antihypertensive drug in the treatment of refractory hypertension. 4. Sodium-potassium channel converting enzyme inhibitor: the main representative drug is Rotafosine (currently not on the market in China), which can change the systemic blood volume and reduce the blood pressure of patients by resisting the influence of wowbine and mutant α-endoprotein on Na+-K+ pump function. In clinical practice, the most appropriate antihypertensive drugs need to be selected under the guidance of specialized doctors according to the specific conditions of patients.